Delayed effects of long-term administration of granulocyte colony-stimulating factor to mice

Bulletin of Experimental Biology and Medicine
I N NifontovaV G Savchenko

Abstract

We studied the effects of chronic administration of granulocyte colony-stimulating factor in nonmobilizing doses to mice. Over 18 months of the study, 55% animals of the treatment group died of unknown cause, blood diseases and tumors were found in 20% mice, and in 5% animals pathological changes were absent. Control mice had no diseases (normal values of total and differential leukocyte count). The diagnoses made over the first 7 months mainly included myeloproliferative diseases. Solid tumors were found at later terms. Suppurative inflammation at the site of injection was observed in all mice after 3-month treatment with granulocyte colony-stimulating factor. Our results indicate that chronic administration of granulocyte colony-stimulating factor in low doses leads to the development of etiologically different tumors and sharply reduced animal life span. The use of granulocyte colony-stimulating factor during allogeneic transplantation of hemopoietic stem cells can be hazardous for donors.

References

Mar 10, 2001·Transfusion·U PlatzbeckerK Hölig
Jun 19, 2002·Blood·Scott C KoganUNKNOWN Hematopathology subcommittee of the Mouse Models of Human Cancers Consortium

❮ Previous
Next ❯

Citations

Jun 17, 2011·International Journal of Radiation Biology·Guy GartyDavid J Brenner
Jul 18, 2012·Bulletin of Experimental Biology and Medicine·O A ZhironkinaN I Drize

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

Blood
Scott C KoganHematopathology subcommittee of the Mouse Models of Human Cancers Consortium
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
Daniel GotthardtPeter Sauer
British Journal of Haematology
Caroline Edijana Omoti, Afekhide Ernest Omoti
© 2021 Meta ULC. All rights reserved